Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery

  • One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion 
  • Lexaria solves this problem with its DehydraTECH(TM) drug delivery technology
  • Since the company began working on this technology back in 2014, it has made major strides in the delivery of hypertension and anti-viral treatments

Since its inception, Lexaria Bioscience (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules in drugs. With its drug delivery technology, DehydraTECH(TM), the company has aided in developing hypertension and anti-viral treatments (https://cnw.fm/xwiio). This is a big achievement for the company and is already making an impact in the pharmaceutical industry.

One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion. Also referred to as the first-pass effect or presystemic metabolism, this is an occurrence where whenever a patient takes a drug orally, it enters the liver and suffers extensive biotransformation to a level where its bioavailability or overall effectiveness is drastically reduced, ultimately showing subtherapeutic action (https://cnw.fm/hU8wV). 

In the past, scientists and pharmaceutical companies have tried to address this by calculating the total quantity of the metabolized drug, with an equivalent amount of excess drug added to the oral formulation. Alternatively, they have tried to explore alternative routes of drug administration, specifically designed to bypass first-pass metabolism. Of the tried and tested workarounds to the issue, some have shown more promise than others. However, nothing comes close to Lexaria’s DehydraTECH.

Since Lexaria began working on this technology in 2014, DehydraTECH has developed considerably and impacted the industry. So far, it has proven useful for potentially treating hypertension, along with the delivery of Colchicine, a drug with known SARS-CoV-2 anti-viral properties (https://cnw.fm/iGVVN).

DehydraTECH is applied by incorporating an intermediate step in the formulation and manufacturing of existing or orally ingestible and topical products. This is a crucial step that entails mixing the active ingredients as a delivery “payload” with specific fatty acids and infusing the mixture into a substrate material. The next step involves using a controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level before integrating the newly-combined molecules into end-product production across various dosage form factors.

From a commercial standpoint, Lexaria’s technology is proving to offer an additional layer that companies that offer consumer supplements, prescription, and non-prescription-based drugs, cannabis, and nicotine products can use to improve the effectiveness of both new and existing products. With over 50 pending patents in countries worldwide, along with 21 granted patents in countries of highest commercial potential such as the US, the EU, Japan and more, Lexaria understands the value of this technology and its usefulness, both to patients and pharmaceutical companies.

Gone are the days of having to calculate the total quantity of the metabolized drug once orally taken. DehydraTECH allows the body to bypass first-pass-liver processing, allowing for smaller doses and effective treatment for specific conditions and ailments. It is a tremendous milestone, not just for Lexaria but also for the medical industry. With what the company has achieved since 2014, it is evident that bigger and better things are to come. 

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX 

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is part of the InvestorBrandNetwork.

Archives

Select A Month

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977